{"id":"ofev","rwe":[{"pmid":"41902501","year":"2026","title":"Multifunctional Toxin-Neutralizing and Antibacterial Cell-Mimicking Liposomes for Effectively Managing Wound Infections and Promoting Scarless Healing.","finding":"","journal":"Advanced healthcare materials","studyType":"Clinical Study"},{"pmid":"41396433","year":"2025","title":"Nerandomilast (Jascayd) for idiopathic pulmonary fibrosis.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"41127528","year":"2025","title":"Eosinophilia associated with nintedanib therapy.","finding":"","journal":"Respiratory medicine case reports","studyType":"Clinical Study"},{"pmid":"40630797","year":"2025","title":"The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.","finding":"","journal":"Canadian respiratory journal","studyType":"Clinical Study"},{"pmid":"40200817","year":"2025","title":"Development of cysteine-sensitive bimodal probes for in situ monitoring of early-stage pulmonary fibrosis progression and therapeutic effects.","finding":"","journal":"Journal of materials chemistry. B","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Boehringer Ingelheim","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":2529.907,"date":"","count":2368,"signal":"Diarrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 2,368 times (LLR=2530)"},{"llr":897.189,"date":"","count":600,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 600 times (LLR=897)"},{"llr":697.303,"date":"","count":1056,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 1,056 times (LLR=697)"},{"llr":645.422,"date":"","count":733,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 733 times (LLR=645)"},{"llr":397.476,"date":"","count":1055,"signal":"Nausea","source":"DrugCentral FAERS","actionTaken":"Reported 1,055 times (LLR=397)"},{"llr":379.28,"date":"","count":594,"signal":"Weight decreased","source":"DrugCentral FAERS","actionTaken":"Reported 594 times (LLR=379)"},{"llr":311.859,"date":"","count":174,"signal":"Pneumothorax","source":"DrugCentral FAERS","actionTaken":"Reported 174 times (LLR=312)"},{"llr":277.812,"date":"","count":845,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 845 times (LLR=278)"},{"llr":222.82,"date":"","count":670,"signal":"Vomiting","source":"DrugCentral FAERS","actionTaken":"Reported 670 times (LLR=223)"},{"llr":197.402,"date":"","count":71,"signal":"Lung transplant","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=197)"},{"llr":192.732,"date":"","count":134,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 134 times (LLR=193)"},{"llr":173.738,"date":"","count":422,"signal":"Cough","source":"DrugCentral FAERS","actionTaken":"Reported 422 times (LLR=174)"},{"llr":173.706,"date":"","count":64,"signal":"Idiopathic pulmonary fibrosis","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=174)"},{"llr":138.317,"date":"","count":243,"signal":"Respiratory failure","source":"DrugCentral FAERS","actionTaken":"Reported 243 times (LLR=138)"},{"llr":131.741,"date":"","count":140,"signal":"Drug-induced liver injury","source":"DrugCentral FAERS","actionTaken":"Reported 140 times (LLR=132)"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Liver enzyme elevation","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight decreased","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypothyroidism","drugRate":"1.1%","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"0.8%","severity":"common","organSystem":""}],"specialPopulations":{"Smokers":"Decreased exposure has been noted in smokers which may alter the efficacy profile of OFEV.","Lactation":"There is no information on the presence of nintedanib in human milk, the effects on the breast-fed infant or the effects on milk production. Nintedanib and/or its metabolites are present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment with OFEV.","Pregnancy":"OFEV can cause fetal harm when administered to pregnant woman. There are no data on the use of OFEV during pregnancy. In animal studies of pregnant rats and rabbits treated during organogenesis, nintedanib caused embryo-fetal deaths and structural abnormalities at less than (rats) and approximately times (rabbits) the maximum recommended human dose. Advise pregnant women of the potential risk to fetus.","Geriatric use":"Of the total number of subjects in phase and clinical studies of OFEV in IPF (Study 1, Study 2, and Study 3), 61% were 65 and over, while 16% were 75 and over. In the chronic fibrosing ILDs with progressive phenotype clinical study (Study 5), 61% were 65 and over, while 19% were 75 and older. In SSc-ILD (Study 4), 21.4% were 65 and over, while 1.9% were 75 and older. In phase studies, no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"The safety and efficacy of OFEV have not been studied in patients with severe renal impairment and end-stage renal disease."},"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"1.5%","severity":"serious"},{"effect":"Bronchitis","drugRate":"1.2%","severity":"serious"},{"effect":"Pneumonia","drugRate":"0.7%","severity":"serious"},{"effect":"Lung neoplasm malignant","drugRate":"0.3%","severity":"serious"}]},"trials":[],"aliases":["Nintedanib"],"company":"Boehringer Ingelheim","patents":[{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2026","useCode":"U-2620","territory":"US","drugProduct":false,"patentNumber":"10154990","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Jun 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9907756","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Jun 4, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10105323","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Expired","expires":"Oct 1, 2025","useCode":"","territory":"US","drugProduct":true,"patentNumber":"6762180","drugSubstance":true},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Apr 1, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"6762180*PED","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Dec 7, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9907756*PED","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Dec 4, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10105323*PED","drugSubstance":false},{"applNo":"N205832","source":"FDA Orange Book","status":"Active","expires":"Jul 8, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10154990*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OFEV®","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:33:34.055850+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:33:34.054941+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:33:53.295111+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:33:40.613894+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OFEV®","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:33:41.519409+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL502835/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:33:42.543661+00:00"}},"allNames":["ofev®"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2014-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BOEHRINGER INGELHEIM to Boehringer Ingelheim"},{"date":"2014-10-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Boehringer Ingelheim)"},{"date":"2014-11-20","type":"positive","source":"DrugCentral","milestone":"EMA approval (Boehringer Ingelheim International GmbH)"},{"date":"2015-07-03","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Boehringer Ingelheim)"},{"date":"2025-10-01","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 6762180 expires"},{"date":"2026-09-06","type":"negative","source":"FDA Orange Book","milestone":"ODE-261 exclusivity expires"},{"date":"2027-03-06","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"}],"aiSummary":"OFEV® is a marketed drug by Boehringer Ingelheim, primarily indicated for idiopathic pulmonary fibrosis, with a key composition patent expiring in 2028. Its key strength lies in its established market presence and specific mechanism of action targeting a critical biological pathway. The primary risk is the competitive landscape, including off-patent drugs like sunitinib and pazopanib, which may erode market share.","approvals":[],"ecosystem":[],"mechanism":{"target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","novelty":"Follow-on","targets":[{"gene":"FLT3","source":"DrugCentral","target":"Receptor-type tyrosine-protein kinase FLT3","protein":"Receptor-type tyrosine-protein kinase FLT3"},{"gene":"MAP2K5","source":"DrugCentral","target":"Dual specificity mitogen-activated protein kinase kinase 5","protein":"Dual specificity mitogen-activated protein kinase kinase 5"},{"gene":"BMP2K","source":"DrugCentral","target":"BMP-2-inducible protein kinase","protein":"BMP-2-inducible protein kinase"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"KIT","source":"DrugCentral","target":"Mast/stem cell growth factor receptor Kit","protein":"Mast/stem cell growth factor receptor Kit"},{"gene":"MAP3K7","source":"DrugCentral","target":"Mitogen-activated protein kinase kinase kinase 7","protein":"Mitogen-activated protein kinase kinase kinase 7"},{"gene":"NTRK1","source":"DrugCentral","target":"High affinity nerve growth factor receptor","protein":"High affinity nerve growth factor receptor"},{"gene":"JAK1","source":"DrugCentral","target":"Tyrosine-protein kinase JAK1","protein":"Tyrosine-protein kinase JAK1"},{"gene":"MELK","source":"DrugCentral","target":"Maternal embryonic leucine zipper kinase","protein":"Maternal embryonic leucine zipper kinase"},{"gene":"KDR","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 2","protein":"Vascular endothelial growth factor receptor 2"}],"moaClass":"Protein Kinase Inhibitors","modality":"Small Molecule","drugClass":"Kinase Inhibitor","explanation":"","oneSentence":"","technicalDetail":"ofev is a small molecule that binds to a specific protein target, modulating its activity and leading to a therapeutic effect."},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=ofev%C2%AE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ofev®","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:40:16.915740","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:33:53.295608+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"sunitinib","drugSlug":"sunitinib","fdaApproval":"2006-01-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sorafenib","drugSlug":"sorafenib","fdaApproval":"2005-12-20","patentExpiry":"Sep 10, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pazopanib","drugSlug":"pazopanib","fdaApproval":"2009-10-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vandetanib","drugSlug":"vandetanib","fdaApproval":"2011-04-06","patentExpiry":"Aug 8, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"regorafenib","drugSlug":"regorafenib","fdaApproval":"2012-09-27","patentExpiry":"Jun 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cabozantinib","drugSlug":"cabozantinib","fdaApproval":"2012-11-29","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lenvatinib","drugSlug":"lenvatinib","fdaApproval":"2015-02-13","patentExpiry":"Sep 3, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"midostaurin","drugSlug":"midostaurin","fdaApproval":"2017-04-28","patentExpiry":"Oct 9, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"quizartinib","drugSlug":"quizartinib","fdaApproval":"2023-07-20","patentExpiry":"Sep 30, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"larotrectinib","drugSlug":"larotrectinib","fdaApproval":"2018-11-26","patentExpiry":"Oct 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gilteritinib","drugSlug":"gilteritinib","fdaApproval":"2018-11-28","patentExpiry":"Nov 28, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"entrectinib","drugSlug":"entrectinib","fdaApproval":"2019-08-15","patentExpiry":"May 22, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pexidartinib","drugSlug":"pexidartinib","fdaApproval":"2019-08-02","patentExpiry":"Nov 21, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capmatinib","drugSlug":"capmatinib","fdaApproval":"2020-05-06","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"avapritinib","drugSlug":"avapritinib","fdaApproval":"2020-01-09","patentExpiry":"Oct 15, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ripretinib","drugSlug":"ripretinib","fdaApproval":"2020-05-15","patentExpiry":"Oct 6, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tepotinib","drugSlug":"tepotinib","fdaApproval":"2021-02-03","patentExpiry":"Oct 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selpercatinib","drugSlug":"selpercatinib","fdaApproval":"2020-05-08","patentExpiry":"Oct 10, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pralsetinib","drugSlug":"pralsetinib","fdaApproval":"2020-09-04","patentExpiry":"Nov 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"umbralisib","drugSlug":"umbralisib","fdaApproval":"2021-02-05","patentExpiry":"May 26, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ofev®","indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis","diseaseId":"idiopathic-pulmonary-fibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Interstitial fibrosis","diseaseId":"interstitial-fibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-small cell lung cancer","diseaseId":"non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic sclerosis associated interstitial lung disease","diseaseId":"systemic-sclerosis-associated-interstitial-lung-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02999178","phase":"PHASE3","title":"Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2017-01-17","conditions":["Lung Diseases, Interstitial"],"enrollment":663,"completionDate":"2019-08-12"},{"nctId":"NCT02597933","phase":"PHASE3","title":"A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2015-11-12","conditions":["Scleroderma, Systemic"],"enrollment":580,"completionDate":"2018-11-28"},{"nctId":"NCT00514683","phase":"PHASE2","title":"Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2007-08","conditions":["Pulmonary Fibrosis"],"enrollment":432,"completionDate":""},{"nctId":"NCT01335464","phase":"PHASE3","title":"Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2011-04","conditions":["Pulmonary Fibrosis"],"enrollment":515,"completionDate":"2013-10"},{"nctId":"NCT01335477","phase":"PHASE3","title":"Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"startDate":"2011-05","conditions":["Pulmonary Fibrosis"],"enrollment":551,"completionDate":"2013-10"},{"nctId":"NCT05503030","phase":"","title":"Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-12-21","conditions":["Lung Diseases, Interstitial"],"enrollment":88,"completionDate":"2026-04-01"},{"nctId":"NCT07491523","phase":"","title":"Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","status":"RECRUITING","sponsor":"University of Patras","startDate":"2025-06-01","conditions":["SSc-Systemic Sclerosis"],"enrollment":35,"completionDate":"2027-03"},{"nctId":"NCT07485920","phase":"PHASE4","title":"A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-05-01","conditions":["Limited-stage Small Cell Lung Cancer (LS-SCLC)"],"enrollment":20,"completionDate":"2030-01-31"},{"nctId":"NCT04325217","phase":"","title":"Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2020-05-27","conditions":["Lung Diseases, Interstitial"],"enrollment":586,"completionDate":"2026-06-30"},{"nctId":"NCT01658462","phase":"PHASE2","title":"Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-05","conditions":["Breast Cancer"],"enrollment":51,"completionDate":"2017-10-30"},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":["Idiopathic Pulmonary Fibrosis","Acute Exacerbation of Idiopathic Pulmonary Fibrosis"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT04976036","phase":"PHASE2","title":"Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients","status":"RECRUITING","sponsor":"Dr. Romain Lazor","startDate":"2022-05-05","conditions":["Telangiectasia, Hereditary Hemorrhagic"],"enrollment":48,"completionDate":"2026-12"},{"nctId":"NCT07454291","phase":"PHASE1","title":"A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Endeavor Biomedicines, Inc.","startDate":"2026-03","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":57,"completionDate":"2026-10"},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":["Systemic Sclerosis"],"enrollment":92,"completionDate":"2030-11-11"},{"nctId":"NCT05285982","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-04-06","conditions":["Lung Diseases, Interstitial"],"enrollment":54,"completionDate":"2025-08-13"},{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":["Acute Exacerbation of Idiopathic Pulmonary Fibrosis"],"enrollment":110,"completionDate":"2026-12-31"},{"nctId":"NCT05799755","phase":"PHASE4","title":"Myositis Interstitial Lung Disease Nintedanib Trial","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2023-08-01","conditions":["Myositis Associated Interstitial Lund Disease (MA-ILD)"],"enrollment":49,"completionDate":"2025-12-31"},{"nctId":"NCT06485635","phase":"","title":"Real-life-persistence to Antifibrotic Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-10-16","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":10646,"completionDate":"2026-03-31"},{"nctId":"NCT05828953","phase":"PHASE2,PHASE3","title":"Anlotinib Capsules in the Treatment for IPF/PF-ILDs","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2021-09-28","conditions":["Interstitial Lung Diseases"],"enrollment":30,"completionDate":"2026-09-09"},{"nctId":"NCT07404423","phase":"","title":"OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"University of Modena and Reggio Emilia","startDate":"2026-06-01","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":1000,"completionDate":"2027-06-01"},{"nctId":"NCT03939520","phase":"PHASE4","title":"Management of Progressive Disease in Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-06-11","conditions":["Progressive Idiopathic Pulmonary Fibrosis"],"enrollment":279,"completionDate":"2026-01-09"},{"nctId":"NCT04559581","phase":"","title":"Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-10-02","conditions":["Lung Diseases, Interstitial"],"enrollment":425,"completionDate":"2025-01-22"},{"nctId":"NCT05195918","phase":"PHASE1","title":"Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2023-08-24","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":50,"completionDate":"2026-04-21"},{"nctId":"NCT03377023","phase":"PHASE1,PHASE2","title":"Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-02-02","conditions":["Non Small Cell Lung Cancer","Lung Cancer, Nonsmall Cell","Non Small Cell Lung Cancer Metastatic"],"enrollment":66,"completionDate":"2026-08"},{"nctId":"NCT02856425","phase":"PHASE1","title":"Trial Of Pembrolizumab And Nintedanib","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-11-10","conditions":["Patients With Any Advanced Solid Tumors"],"enrollment":196,"completionDate":"2026-01-10"},{"nctId":"NCT07344558","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Mannkind Corporation","startDate":"2025-12-22","conditions":["Idiopathic Pulmonary Fibrosis (IPF)"],"enrollment":24,"completionDate":"2026-04-01"},{"nctId":"NCT05497284","phase":"PHASE2","title":"To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-10","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":46,"completionDate":"2024-09-26"},{"nctId":"NCT07332117","phase":"","title":"A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2025-09-09","conditions":["Idiopathic Pulmonary Fibrosis (IPF)","Progressive Pulmonary Fibrosis"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT06717100","phase":"PHASE1","title":"Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib","status":"COMPLETED","sponsor":"PureTech","startDate":"2024-12-17","conditions":["Drug Interactions"],"enrollment":24,"completionDate":"2025-03-17"},{"nctId":"NCT06912659","phase":"","title":"The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-23","conditions":["Pulmonary Fibrosis"],"enrollment":157,"completionDate":"2026-12-23"},{"nctId":"NCT06714812","phase":"","title":"Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-08-20","conditions":["IPF"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT03805477","phase":"PHASE2","title":"Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-03-20","conditions":["Bronchiolitis Obliterans Syndrome (BOS)","Bronchiolitis Obliterans (BO)"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":["Interstitial Lung Diseases","Systemic Sclerosis Associated Interstitial Lung Disease"],"enrollment":2000,"completionDate":"2033-12-31"},{"nctId":"NCT06070610","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-11-08","conditions":["Healthy"],"enrollment":14,"completionDate":"2023-12-14"},{"nctId":"NCT07229716","phase":"PHASE1","title":"Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-11","conditions":["Pulmonary Fibrosis"],"enrollment":20,"completionDate":"2026-04"},{"nctId":"NCT05151640","phase":"","title":"INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-02-08","conditions":["Lung Diseases, Interstitial"],"enrollment":158,"completionDate":"2025-09-05"},{"nctId":"NCT03513484","phase":"PHASE1","title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2018-11-14","conditions":["Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Fibroblast Growth Factor Basic Form Measurement","FLT3 Internal Tandem Duplication","Recurrent Adult Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":44,"completionDate":"2027-01"},{"nctId":"NCT07015398","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2025-06-30","conditions":["Healthy Participants"],"enrollment":132,"completionDate":"2025-09-26"},{"nctId":"NCT07194382","phase":"PHASE2","title":"AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF","status":"NOT_YET_RECRUITING","sponsor":"Avalyn Pharma Inc.","startDate":"2026-01","conditions":["Idiopathic Pulmonary Fibrosis (IPF)"],"enrollment":160,"completionDate":"2027-06"},{"nctId":"NCT02863055","phase":"PHASE2","title":"Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2018-02-04","conditions":["Malignant Pleural Mesothelioma"],"enrollment":37,"completionDate":"2024-01-10"},{"nctId":"NCT07162961","phase":"PHASE3","title":"Nintedanib for Improving Reproductive Outcomes in Adenomyosis","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-01","conditions":["Adenomyosis of Uterus"],"enrollment":328,"completionDate":"2027-06-30"},{"nctId":"NCT03283007","phase":"PHASE3","title":"Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-10-30","conditions":["Lung-transplant Recipients"],"enrollment":58,"completionDate":"2025-03-30"},{"nctId":"NCT05335278","phase":"NA","title":"Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-01","conditions":["Interstitial Lung Disease","Myopathy, Inflammatory"],"enrollment":11,"completionDate":"2025-04-30"},{"nctId":"NCT04614441","phase":"","title":"NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-01-21","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":214,"completionDate":"2025-05-14"},{"nctId":"NCT03954782","phase":"PHASE2","title":"Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-06-22","conditions":["Telangiectasia, Hereditary Hemorrhagic","Rendu Osler Disease"],"enrollment":61,"completionDate":"2023-02-24"},{"nctId":"NCT02730416","phase":"PHASE2","title":"Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer","status":"COMPLETED","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2016-12-12","conditions":["Endometrial Cancer"],"enrollment":146,"completionDate":"2021-11-25"},{"nctId":"NCT05779007","phase":"","title":"Dose Reduction and Discontinuation With Anti-Fibrotic Medications","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-04-18","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":2778,"completionDate":"2023-07-14"},{"nctId":"NCT02392455","phase":"","title":"VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-03-23","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":817,"completionDate":"2025-07-23"},{"nctId":"NCT06200714","phase":"","title":"A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-07-16","conditions":["Idiopathic Pulmonary Fibrosis","Diarrhoea"],"enrollment":17,"completionDate":"2025-04-29"},{"nctId":"NCT02299141","phase":"PHASE2","title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-05-07","conditions":["Carcinoma, Non-Small-Cell Lung","Non-Small Cell Lung Cancer","Nonsmall Cell Lung Cancer"],"enrollment":20,"completionDate":"2025-04-23"},{"nctId":"NCT06742502","phase":"PHASE2","title":"Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":["Primary Mediastinal Diffuse Large B-cell Lymphoma"],"enrollment":30,"completionDate":"2029-12-30"},{"nctId":"NCT05065190","phase":"PHASE3","title":"A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-11-25","conditions":["Lung Diseases, Interstitial"],"enrollment":81,"completionDate":"2024-05-07"},{"nctId":"NCT03047031","phase":"","title":"Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-04-05","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":21,"completionDate":"2022-07-21"},{"nctId":"NCT04702893","phase":"","title":"INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-05-28","conditions":["Lung Diseases, Interstitial"],"enrollment":108,"completionDate":"2024-04-09"},{"nctId":"NCT02496585","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-07-08","conditions":["Lung Cancer","Lung Metastases"],"enrollment":34,"completionDate":"2024-04-12"},{"nctId":"NCT05483907","phase":"PHASE2","title":"To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF","status":"COMPLETED","sponsor":"Bridge Biotherapeutics, Inc.","startDate":"2023-04-12","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":129,"completionDate":"2025-02-23"},{"nctId":"NCT06568458","phase":"PHASE1","title":"A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-09-19","conditions":["Healthy Participants"],"enrollment":71,"completionDate":"2025-02-27"},{"nctId":"NCT00979576","phase":"PHASE1","title":"BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2009-10-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":19,"completionDate":"2015-02-16"},{"nctId":"NCT05067517","phase":"PHASE3","title":"Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2021-11","conditions":["Progressive Fibrosing Interstitial Lung Disease"],"enrollment":0,"completionDate":"2024-07"},{"nctId":"NCT04619680","phase":"PHASE4","title":"The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-11-18","conditions":["Pulmonary Fibrosis","Interstitial Lung Disease","Respiratory Disease"],"enrollment":121,"completionDate":"2024-03-02"},{"nctId":"NCT06625489","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-10-07","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":50,"completionDate":"2024-11-25"},{"nctId":"NCT01314105","phase":"PHASE1","title":"BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03-15","conditions":["Ovarian Neoplasms","Peritoneal Neoplasms"],"enrollment":19,"completionDate":"2016-04-04"},{"nctId":"NCT02231164","phase":"PHASE3","title":"LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-14","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":12,"completionDate":"2015-12-24"},{"nctId":"NCT01346540","phase":"PHASE1","title":"A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04-14","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":16,"completionDate":"2017-01-17"},{"nctId":"NCT02300298","phase":"PHASE1","title":"Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-12-24","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":10,"completionDate":"2017-10-27"},{"nctId":"NCT02780700","phase":"PHASE2","title":"Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2016-07-05","conditions":["Colorectal Neoplasms"],"enrollment":1,"completionDate":"2016-09-09"},{"nctId":"NCT02182245","phase":"PHASE1","title":"Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10-01","conditions":["Genital Neoplasms, Female"],"enrollment":22,"completionDate":""},{"nctId":"NCT06071013","phase":"PHASE1,PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":["Non-small Cell Lung Cancer","EGFR Gene Mutation","EGFR-TKI Resistant Mutation"],"enrollment":20,"completionDate":"2026-08-27"},{"nctId":"NCT02182219","phase":"PHASE1","title":"Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11-01","conditions":["Prostatic Neoplasms"],"enrollment":21,"completionDate":""},{"nctId":"NCT02551068","phase":"NA","title":"High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2015-12","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":88,"completionDate":"2026-12"},{"nctId":"NCT05830799","phase":"PHASE1","title":"A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2023-03-29","conditions":["Drug Interaction"],"enrollment":19,"completionDate":"2023-05-11"},{"nctId":"NCT05676112","phase":"","title":"Safety of Nintedanib in Real World in China","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2023-12-29","conditions":["Pulmonary Fibrosis"],"enrollment":0,"completionDate":"2026-09-30"},{"nctId":"NCT03843892","phase":"","title":"An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities","status":"APPROVED_FOR_MARKETING","sponsor":"Boehringer Ingelheim","startDate":"","conditions":["Lung Diseases, Interstitial"],"enrollment":0,"completionDate":""},{"nctId":"NCT06297096","phase":"PHASE3","title":"Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-01","conditions":["Systemic Sclerosis","Interstitial Lung Disease"],"enrollment":86,"completionDate":"2028-03-30"},{"nctId":"NCT06479603","phase":"PHASE4","title":"RCT of Nintedanib in Fibrotic Sarcoidosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-06-30","conditions":["Sarcoidosis, Pulmonary"],"enrollment":120,"completionDate":"2026-01-31"},{"nctId":"NCT06650774","phase":"","title":"Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2024-06-15","conditions":["Idiopathic Pulmonary Fibrosis (IPF)"],"enrollment":152,"completionDate":"2024-09-30"},{"nctId":"NCT02607722","phase":"","title":"All-Case Surveillance of Ofev in Patients With IPF in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-08-31","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":10117,"completionDate":"2023-05-02"},{"nctId":"NCT06643091","phase":"PHASE2","title":"Nintedanib Treatment in Unicentric Castleman Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-01","conditions":["Castleman Disease"],"enrollment":13,"completionDate":"2030-09-01"},{"nctId":"NCT05870956","phase":"","title":"Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-05-16","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":1798,"completionDate":"2023-06-30"},{"nctId":"NCT04971746","phase":"PHASE1","title":"Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2021-07-19","conditions":["Healthy"],"enrollment":58,"completionDate":"2022-05-09"},{"nctId":"NCT06570317","phase":"","title":"Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC","status":"RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2024-08-24","conditions":["NSCLC","Nintedanib","Radiation Pneumonitis"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT02009579","phase":"PHASE2","title":"ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer","status":"COMPLETED","sponsor":"Belgian Gynaecological Oncology Group","startDate":"2014-03","conditions":["Uterine Cervical Neoplasms"],"enrollment":120,"completionDate":"2023-10"},{"nctId":"NCT06532942","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers","status":"RECRUITING","sponsor":"Mannkind Corporation","startDate":"2024-05-28","conditions":["Healthy Volunteers"],"enrollment":40,"completionDate":"2024-10-31"},{"nctId":"NCT03710824","phase":"","title":"Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-02-28","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":180,"completionDate":"2023-02-22"},{"nctId":"NCT04093024","phase":"PHASE3","title":"A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-03","conditions":["Lung Diseases, Interstitial"],"enrollment":39,"completionDate":"2022-05-24"},{"nctId":"NCT06482190","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers","status":"RECRUITING","sponsor":"Shenzhen Resproly Biopharmaceutical Co., Ltd","startDate":"2024-07-11","conditions":["Idiopathic Pulmonary Fibrosis","Lung; Disease, Interstitial, With Fibrosis"],"enrollment":72,"completionDate":"2025-02-10"},{"nctId":"NCT03287414","phase":"PHASE2","title":"Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-20","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":30,"completionDate":"2022-02-14"},{"nctId":"NCT02902484","phase":"PHASE1,PHASE2","title":"Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-09-07","conditions":["Cancer of Pancreas"],"enrollment":14,"completionDate":"2021-10-26"},{"nctId":"NCT05262751","phase":"PHASE1","title":"A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-03-28","conditions":["Healthy"],"enrollment":21,"completionDate":"2022-11-30"},{"nctId":"NCT04541680","phase":"PHASE3","title":"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-29","conditions":["SARS-Cov-2 Induced Pulmonary Fibrosis"],"enrollment":250,"completionDate":"2024-07"},{"nctId":"NCT02225405","phase":"PHASE1","title":"Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-03","conditions":["Stage IB Non-Small Cell Lung Carcinoma AJCC v7","Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7"],"enrollment":26,"completionDate":"2024-05-06"},{"nctId":"NCT05022784","phase":"","title":"Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-23","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":1798,"completionDate":"2021-12-30"},{"nctId":"NCT03017885","phase":"","title":"Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-02-28","conditions":["Non-small Cell Lung Cancer"],"enrollment":28,"completionDate":"2022-09-24"},{"nctId":"NCT04525547","phase":"","title":"Safety and Effectiveness of Nintedanib in Korean Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-01-13","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":70,"completionDate":"2022-08-18"},{"nctId":"NCT03313180","phase":"PHASE3","title":"A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-11-27","conditions":["Lung Diseases, Interstitial"],"enrollment":444,"completionDate":"2023-01-25"},{"nctId":"NCT05644600","phase":"PHASE1","title":"A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2023-05-26","conditions":["Healthy Subjects"],"enrollment":18,"completionDate":"2023-07-17"},{"nctId":"NCT04046614","phase":"PHASE1,PHASE2","title":"Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-05-25","conditions":["Adenocarcinoma of the Lung"],"enrollment":56,"completionDate":"2023-09-15"},{"nctId":"NCT05624281","phase":"","title":"A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)","status":"NO_LONGER_AVAILABLE","sponsor":"Boehringer Ingelheim","startDate":"","conditions":["Lung Diseases, Interstitial (in Pediatric Populations)","Childhood Interstitial Lung Disease (chILD)"],"enrollment":0,"completionDate":""},{"nctId":"NCT02399215","phase":"PHASE2","title":"Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-15","conditions":["Carcinoid Tumor","Metastatic Carcinoid Tumor","Neuroendocrine Neoplasm"],"enrollment":32,"completionDate":"2022-08-31"},{"nctId":"NCT02788474","phase":"PHASE4","title":"Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-06-09","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":347,"completionDate":"2018-06-08"},{"nctId":"NCT05817240","phase":"PHASE1","title":"A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects","status":"COMPLETED","sponsor":"Endeavor Biomedicines, Inc.","startDate":"2023-05-03","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":21,"completionDate":"2023-06-21"},{"nctId":"NCT03820726","phase":"PHASE3","title":"A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-04-16","conditions":["Lung Diseases, Interstitial"],"enrollment":435,"completionDate":"2022-08-30"},{"nctId":"NCT05755308","phase":"NA","title":"Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-10","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":114,"completionDate":"2026-04"},{"nctId":"NCT01583322","phase":"PHASE2","title":"Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2012-06","conditions":["Ovarian Cancer"],"enrollment":188,"completionDate":"2016-03"},{"nctId":"NCT04938453","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-07-14","conditions":["Healthy"],"enrollment":20,"completionDate":"2021-08-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL502835"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"Boehringer Ingelheim","relationship":"Original Developer"},{"period":"2014","companyName":"Boehringer Ingelheim International GmbH","relationship":"EMA Licensee"}],"publicationCount":37,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Boehringer Ingelheim","recentPublications":[{"date":"2026 Mar 28","pmid":"41902501","title":"Multifunctional Toxin-Neutralizing and Antibacterial Cell-Mimicking Liposomes for Effectively Managing Wound Infections and Promoting Scarless Healing.","journal":"Advanced healthcare materials"},{"date":"2025 Dec 22","pmid":"41396433","title":"Nerandomilast (Jascayd) for idiopathic pulmonary fibrosis.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2025","pmid":"41127528","title":"Eosinophilia associated with nintedanib therapy.","journal":"Respiratory medicine case reports"},{"date":"2025","pmid":"40630797","title":"The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.","journal":"Canadian respiratory journal"},{"date":"2025 May 1","pmid":"40200817","title":"Development of cysteine-sensitive bimodal probes for in situ monitoring of early-stage pulmonary fibrosis progression and therapeutic effects.","journal":"Journal of materials chemistry. B"}],"_revenueClearedDupe":"nintedanib","companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"OFEV®","companyName":"Boehringer Ingelheim","companyId":"boehringer-ingelheim","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:33:53.295608+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}